Ocular Therapeutix, Inc. (OCUL) Stock Price & How to Invest
Short answer
You can invest in Ocular Therapeutix (OCUL) by buying shares or fractional shares at any major broker, through a biotech ETF that holds it, or as one holding in a thematic basket. OCUL is a clinical-and-commercial-stage eye-disease biotech whose story is really a bet on one drug: AXPAXLI, an injectable sustained-release treatment for wet age-related macular degeneration that recently beat the standard of care in a Phase 3 trial. It is a high-risk, catalyst-driven biotech, not an income or value stock.
OCUL stock price
As of 2026-07-08, Ocular Therapeutix, Inc. (OCUL) last closed at $10.27, down 4.6% over the past year. Over the past 52 weeks it has traded between $6.88 and $16.11.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Ocular Therapeutix, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Ocular Therapeutix, Inc. (OCUL) do?
Ocular Therapeutix is a Massachusetts-based biopharmaceutical company focused on diseases and conditions of the eye, built around its proprietary bioresorbable hydrogel technology that delivers drugs to the eye over an extended period from a single administration. Its only approved, revenue-generating product is DEXTENZA, a dexamethasone insert placed in the tear duct to treat inflammation and pain after eye surgery and, more recently, allergic eye itching. DEXTENZA generates modest, roughly flat sales, so the company is effectively pre-profit and funds itself with a large cash balance while it invests heavily in clinical development.
The investment picture is dominated by AXPAXLI (axitinib intravitreal implant), a hydrogel that slowly releases a tyrosine kinase inhibitor to suppress the abnormal blood-vessel growth behind wet AMD and other retinal diseases. In its Phase 3 SOL-1 trial, AXPAXLI met a superiority endpoint versus the anti-VEGF drug aflibercept (Eylea) with a highly statistically significant result, positioning Ocular to pursue an FDA filing and a potential label advantage in a multi-billion-dollar market. Additional Phase 3 trials (SOL-R, HELIOS-3) and a diabetic-retinopathy program are underway. The company reported about $666.7 million of cash as of March 31, 2026, giving a runway into 2028, but it also posts large and widening net losses as R&D spending scales.
What's driving Ocular Therapeutix, Inc. (OCUL)?
1. AXPAXLI in wet AMD.
The lead asset is a sustained-release axitinib implant aimed at reducing the frequent anti-VEGF injections wet-AMD patients currently need. In the Phase 3 SOL-1 trial it met a superiority primary endpoint versus aflibercept (p=0.0006), with a larger share of patients maintaining vision. A durability and label advantage over standard care is the central driver of the company's value.
2. Expanding Phase 3 pipeline.
Beyond SOL-1, Ocular is running the SOL-R registrational trial and the HELIOS-3 study, and it has advanced programs in non-proliferative diabetic retinopathy. Success across multiple retinal indications would broaden AXPAXLI's addressable market well past wet AMD, though each trial adds cost and its own binary risk.
3. Approved product plus hydrogel platform.
DEXTENZA provides real, if modest, commercial revenue (around $52 million in 2025) and a fielded sales infrastructure. The underlying bioresorbable hydrogel delivery platform is reusable across drugs and diseases, giving the company a technology base that could support additional products over time.
4. Well-funded balance sheet.
Cash of about $666.7 million as of March 31, 2026, is expected to fund operations, including multiple Phase 3 programs, into 2028. That runway lets Ocular pursue AXPAXLI approval without immediate financing pressure, although continued heavy R&D spending steadily consumes the balance.
What are the risks to Ocular Therapeutix, Inc. (OCUL)?
The stock is a high-risk, single-asset biotech: most of its value depends on AXPAXLI clearing remaining trials, winning FDA approval, and then being adopted by retina specialists who are comfortable with established anti-VEGF drugs. Wet AMD is intensely competitive, with entrenched blockbusters like Regeneron's Eylea and Roche's Vabysmo plus other long-acting and gene-therapy approaches in development. The company is deeply unprofitable, posting a net loss of about $88.6 million in the first quarter of 2026 as R&D climbed, and it may need additional capital that could dilute shareholders. Regulatory setbacks, trial delays, safety findings, or slower-than-hoped commercial uptake could each move the shares sharply lower, and DEXTENZA revenue is too small to cushion a pipeline disappointment.
How is Ocular Therapeutix, Inc. (OCUL) valued? (approximate, MAY 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Ocular Therapeutix, Inc.'s investor relations page or your broker.
- Revenue (FY2025): ~$52 million
- Revenue (Q1 2026): ~$10.8 million
- Net loss (Q1 2026): ~-$88.6 million
- R&D expense (Q1 2026): ~$66.2 million
- Cash and equivalents (Mar 31, 2026): ~$666.7 million
- Market cap: ~$1.8 billion
Ocular is effectively a pre-profit biotech: DEXTENZA sales were roughly flat and small while R&D spending rose to fund several Phase 3 trials, widening the net loss. The market capitalization of around $1.8 billion is many times trailing revenue because investors are pricing the potential of AXPAXLI rather than current earnings, which is typical for a clinical-stage biotech with a de-risked lead asset.
Who competes with Ocular Therapeutix, Inc. (OCUL)?
Wet-AMD anti-VEGF leaders
Regeneron (Eylea and high-dose Eylea) and Roche/Genentech (Vabysmo) dominate wet AMD today with widely used anti-VEGF injections. AXPAXLI is designed to compete on dosing durability, so these established, well-reimbursed drugs are the direct comparators any new entrant must displace.
Sustained-delivery and next-generation retina players
Companies pursuing longer-acting or novel retinal therapies, such as EyePoint Pharmaceuticals and Roche's Susvimo refillable implant, along with gene-therapy developers, target the same goal of fewer treatments. They compete with AXPAXLI on the promise of reduced injection burden.
Ophthalmic surgical and specialty biotechs
For DEXTENZA and its broader eye-care platform, Ocular competes with larger ophthalmology franchises like Alcon, Bausch + Lomb, and AbbVie's Allergan eye-care unit, which market post-surgical and dry-eye products and have far greater commercial scale.
How to invest in Ocular Therapeutix, Inc. (OCUL)
There are three common ways to get OCUL exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so OCUL sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where OCUL fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Ocular Therapeutix, Inc. (OCUL)
Ocular Therapeutix is a small-cap ophthalmology biotech that already sells one approved product (DEXTENZA) but whose valuation rides almost entirely on its lead pipeline drug AXPAXLI reaching FDA approval and commercial adoption in a large, crowded wet-AMD market. It tends to move sharply on trial data and regulatory news, so the odds and timing of AXPAXLI matter far more than current revenue.
More on Ocular Therapeutix, Inc. (OCUL)
Whether OCUL is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is OCUL a buy?, and where the stock could go from here in the OCUL stock forecast.
For income investors, whether OCUL pays a dividend and how the payout looks is covered in does OCUL pay a dividend?
Build a basket around OCUL with Walnut
Use Ocular Therapeutix, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Ocular Therapeutix do?
+
It is a biopharmaceutical company focused on eye diseases. It sells one approved product, DEXTENZA, for post-surgical eye inflammation and pain, and is developing AXPAXLI, a sustained-release implant for wet age-related macular degeneration and other retinal conditions, using its bioresorbable hydrogel delivery technology.
What is AXPAXLI and why does it matter?
+
AXPAXLI is an injectable hydrogel implant that slowly releases axitinib, a tyrosine kinase inhibitor, to suppress abnormal blood-vessel growth in the retina. It matters because it aims to reduce how often wet-AMD patients need injections, and it recently beat standard care in a Phase 3 trial, making it the main driver of the company's value.
Is Ocular Therapeutix profitable?
+
No. As of early 2026 it was reporting large and widening net losses, including about $88.6 million in the first quarter of 2026, as research and development spending scaled. Its DEXTENZA revenue (around $52 million in 2025) is far too small to cover its clinical-development costs.
How much cash does the company have?
+
Ocular reported about $666.7 million in cash and equivalents as of March 31, 2026, which management expects to fund planned operations, including multiple Phase 3 programs, into 2028. A strong balance sheet reduces near-term financing pressure but continued heavy spending steadily draws it down.
Who are Ocular Therapeutix's main competitors?
+
In wet AMD its key comparators are the established anti-VEGF drugs Eylea from Regeneron and Vabysmo from Roche, plus other sustained-delivery and gene-therapy developers. For its surgical eye products it competes with large ophthalmology franchises like Alcon, Bausch + Lomb, and AbbVie's Allergan.
Why is the market cap so high relative to revenue?
+
At roughly $1.8 billion, the market capitalization is many times trailing revenue because investors are valuing the future potential of AXPAXLI in a multi-billion-dollar wet-AMD market rather than current sales. This is typical for a clinical-stage biotech whose lead drug has shown positive Phase 3 data.
What are the biggest risks with OCUL?
+
It is largely a single-asset biotech, so its value hinges on AXPAXLI completing trials, gaining FDA approval, and being adopted despite entrenched competitors. Risks include regulatory setbacks, trial delays, safety findings, potential dilution from raising capital, and a slow commercial ramp, any of which could move the stock sharply.
How can I invest in Ocular Therapeutix?
+
OCUL trades on the Nasdaq, so you can buy shares or fractional shares through any major broker, gain exposure through biotech ETFs that hold it, or include it as one position in a thematic basket. Because it is a volatile catalyst-driven biotech, many investors size it as a small, speculative slice of a diversified portfolio. Walnut is not an investment adviser.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Ocular Therapeutix, Inc.'s investor relations page or your broker before making investment decisions.